Softcover. Zustand: Bon. Ancien livre de bibliothèque avec équipements. Edition 1985. Ammareal reverse jusqu'à 15% du prix net de cet article à des organisations caritatives. ENGLISH DESCRIPTION Book Condition: Used, Good. Former library book. Edition 1985. Ammareal gives back up to 15% of this item's net price to charity organizations.
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
EUR 60,65
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. In.
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 78,47
Anzahl: 2 verfügbar
In den WarenkorbPaperback. Zustand: Brand New. 208 pages. German language. 9.61x6.70x0.44 inches. In Stock.
Anbieter: Kennys Bookstore, Olney, MD, USA
Zustand: New. Series: Agents and Actions, Supplements. Num Pages: 203 pages, 8 black & white illustrations, biography. BIC Classification: YQS. Category: (G) General (US: Trade). Dimension: 244 x 170 x 11. Weight in Grams: 545. . 1985. Softcover reprint of the original 1st ed. 1985. Paperback. . . . . Books ship from the US and Ireland.
Sprache: Englisch
Verlag: Birkhäuser Basel, Springer Basel, 1985
ISBN 10: 3764317507 ISBN 13: 9783764317508
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly prescribed groups of drugs in the community. This reflects the high frequency of rheumatic complaints but may in part be due to the relative non efficacy of these drugs. Since the introduction of ibuprofen, the first new NSAID to compete with aspirin, phenylbutazone and indomethacin, there has been a proliferation of new NSAIDs of differing chemical classes but an apparent similar spectrum of action. Despite the fact that these drugs are thought to work by an apparent common mechanism of action (suppression of prostaglandin synthetase activity) continued development of these drugs occurs. There exists at present a conflict between the pharmaceutical industry with its attempts to introduce new NSAIDs and drug regulatory authorities who are generally not convinced of the need for additional drugs of_ this class. The practising clinician regards a variety of NSAIDs as necessary to enable pain relief to be optimised.with minimal adverse effects. With respect to the dilemma of how many NSAIDs are really necessary surprisingly little convincing data is available to assist in resolving this issue. It was therefore decided to hold a satellite meeting to the XVIth International League Against Rheumatism Conference in May 1985.